These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3196524)

  • 1. Effect of desferrioxamine infusion on red blood cell aluminum.
    Umeda M; Umimoto K; Tsurusaki K; Izumi N; Kishimoto T; Maekawa M
    ASAIO Trans; 1988; 34(3):297-9. PubMed ID: 3196524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Red blood cell aluminum in patients with renal failure and effect of desferrioxamine infusion.
    Umeda M; Tsurusaki K; Kamikawa S; Izumi N; Yasumoto R; Kishimoto T; Maekawa M
    Blood Purif; 1990; 8(5):295-300. PubMed ID: 2091689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Removal of aluminum from chronic dialysis patients by administration of desferrioxamine and dialysis.
    Ono T; Iwamoto N; Kataoka H; Taniguchi Y; Sakai Y; Kunitomo T
    ASAIO Trans; 1986; 32(1):52-7. PubMed ID: 3778761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Removal of aluminum during hemodialysis: effect of different dialyzer membranes.
    Muirhead N; Hollomby DJ; Leung FY; Mitton R; Henderson AR; Keown PA; Stiller CR
    Am J Kidney Dis; 1986 Jul; 8(1):51-5. PubMed ID: 3728462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The causes, diagnosis and treatment of aluminum toxicity in patients with chronic renal failure undergoing dialysis].
    Wang G; Zhu P; Wang S
    Zhonghua Nei Ke Za Zhi; 1996 Jan; 35(1):36-40. PubMed ID: 9275645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desferrioxamine in the treatment of aluminum overload.
    Ackrill P; Day JP
    Clin Nephrol; 1985; 24 Suppl 1():S94-7. PubMed ID: 3842106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous ambulatory EEG monitoring following desferrioxamine (DFO) i.v. infusion.
    Poignet JL; Monge MF; Ciancioni C; Mikol F; Naret C; Delons S; Man NK
    Trans Am Soc Artif Intern Organs; 1985; 31():546-51. PubMed ID: 3837504
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity.
    McCarthy JT; Milliner DS; Johnson WJ
    Q J Med; 1990 Mar; 74(275):257-76. PubMed ID: 2117295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of aluminum in the pathogenesis of anemia in an outpatient hemodialysis population.
    Yuan B; Klein MH; Contiguglia RS; Mishell JL; Seligman PA; Miller NL; Molitoris BA; Alfrey AC; Shapiro JI
    Ren Fail; 1989; 11(2-3):91-6. PubMed ID: 2623200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low percentage of aluminoxamine and ferrioxamine in uremic serum after desferrioxamine administration.
    Menéndez-Fraga P; Fernández-Martín JL; Blanco-González E; Cannata-Andía JB
    Clin Chem; 1998 Jun; 44(6 Pt 1):1262-8. PubMed ID: 9625051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of anaemia with desferrioxamine in haemodialysis patients.
    Praga M; Andrés A; de la Serna J; Ruilope LM; Nieto J; Estenoz J; Millet VG; Arnaiz F; Rodicio JL
    Nephrol Dial Transplant; 1987; 2(4):243-7. PubMed ID: 3118265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of dialysis osteomalacia and dementia, using desferrioxamine infusions and oral 1-alpha hydroxycholecalciferol.
    Hood SA; Clark WF; Hodsman AB; Bolton CF; Cordy PE; Anderson C; Leung F
    Am J Nephrol; 1984; 4(6):369-74. PubMed ID: 6517116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary zinc excretion and zinc status of patients with beta-thalassemia major.
    Aydinok Y; Coker C; Kavakli K; Polat A; Nisli G; Cetiner N; Kantar M; Cetingül N
    Biol Trace Elem Res; 1999 Nov; 70(2):165-72. PubMed ID: 10535525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of aluminum overload using a cartridge with immobilized desferrioxamine.
    Anthone S; Ambrus CM; Kohli R; Min I; Anthone R; Stadler A; Stadler I; Vladutiu A
    J Am Soc Nephrol; 1995 Oct; 6(4):1271-7. PubMed ID: 8589296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of anemia with deferoxamine in hemodialysis patients with aluminum-induced bone disease.
    Tielemans C; Collart F; Wens R; Smeyers-Verbeeke J; van Hooff I; Dratwa M; Verbeelen D
    Clin Nephrol; 1985 Nov; 24(5):237-41. PubMed ID: 4075595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules.
    Barata JD; D'Haese PC; Pires C; Lamberts LV; Simões J; De Broe ME
    Nephrol Dial Transplant; 1996 Jan; 11(1):125-32. PubMed ID: 8649620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy and safety of long-term and low-dose desferrioxamine therapy against hyperaluminemia and the clinical symptoms associated with hyperaluminemia in patients undergoing maintenance hemodialysis].
    Kuramochi G
    Nihon Jinzo Gakkai Shi; 1989 Mar; 31(3):267-73. PubMed ID: 2739124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid removal of DFO-chelated aluminum during hemodialysis using polysulfone dialyzers.
    Molitoris BA; Alfrey AC; Alfrey PS; Miller NL
    Kidney Int; 1988 Jul; 34(1):98-101. PubMed ID: 3172641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis of aluminum-related bone disease and treatment of aluminum toxicity with deferoxamine.
    Coburn JW; Norris KC
    Semin Nephrol; 1986 Dec; 6(4 Suppl 1):12-21. PubMed ID: 3299588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Aluminum poisoning in dialysis patients--diagnosis and therapy].
    Vogelsang U
    Schweiz Rundsch Med Prax; 1994 Jun; 83(24):738-56. PubMed ID: 8023059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.